Coherus BioSciences (CHRS) Misses Q3 EPS by 1c, Misses on Revenue

Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of ($0.33), $0.01 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $11.6 million versus the consensus estimate of $13.36 million.

For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August